FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Antipsychotic Drugs Market Overview:

According to FutureWise analysis, the market for Antipsychotic Drugs in 2023 is US$ 15.74 billion, and is expected to reach US$ 29.61 billion by 2031 at a CAGR of 8.20%.

Antipsychotics are psychiatric medications used to treat a variety of psychotic symptoms, such as hallucinations, delusions, or manic symptoms. Antipsychotic medications can be administered in various methods, but the most popular is oral administration in liquid or tablet form. Some antipsychotic medications are also given as depot injections. This route of administration results in a slow-acting pharmaceutical release and the injection is given every few weeks. Antipsychotic drugs are prescribed to modulate the brain circuits responsible for perception, thought, and emotion.

Based on their unique action and affinity for particular neurotransmitter receptors, antipsychotic medications are divided into three groups: conventional antipsychotics, 2nd-generation antipsychotics (SGAs), and 3rd-generation antipsychotics. SGAS offers a specific set of benefits regarding effectiveness and minimum side effects. According to recent studies, the majority of antipsychotics administered in the US are new antipsychotic medications like muscarinic agonists, trace amines with unique effects, and SGAS.

FutureWise Market Research has published a report that provides an insightful analysis of antipsychotic drugs market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the antipsychotic drugs market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

Major players included in the Antipsychotic Drugs Market:

AstraZeneca
Pfizer, Inc.
Eli Lily and Co.
Bristol- Myers Squibb
Johnson And Johnson
Allergen
GlaxoSmithKline plc
Otsuka Pharmaceutical Co, Ltd.
AbbVie Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Antipsychotic Drugs Market:

In January 2022-The US Food and Drug Administration approved the supplemental new drug application for REXULTI for Schizophrenia in Patients Aged 13 to 17 Years, according to a statement from Otsuka Pharmaceutical Co., Ltd., its subsidiary Otsuka American Pharmaceutical, Inc., and Lundbeck, Inc.

In recent years, there has been a significant rise in the number of individuals who experience mental health issues. Antipsychotic drugs are in higher demand as a result of the rising prevalence of psychotic diseases such as schizophrenia, bipolar disorder, and depression. For instance, a severe mental illness called schizophrenia causes the patient to have abnormal thinking, acting, feeling, and sense of self. If left untreated, this condition may make death more likely. As a result, many different companies are focusing on creating new drugs to cure this ailment. Chlorpromazine, Olanzapine, Aripiprazole, and other FDA-approved medications are among the numerous ones now available in the market. The prevalence of psychotic disorders and illnesses is predicted to promote the growth of the antipsychotic medication market throughout the forecast period. Furthermore, the prevalence of mental diseases is rising, placing pressure on the healthcare system. The government is focusing its efforts on raising public awareness of the ailments and the efficacy of the therapies employed to treat them. As a result, there has been a rise in demand for highly efficient and secure medications to treat people with psychotic diseases worldwide. Additionally, the companies are concentrating on creating cutting-edge antipsychotic injectable medications that would assist in doing away with the need for patients to be monitored for drug use. Consequently, a large number of pharmaceutical companies have introduced long-acting injectable antipsychotic medications. Due to the advantages of these long-acting injectables, these medications are now being used more frequently, driving market expansion. However, Antipsychotic medications can have more detrimental side effects than advantageous ones. Aside from being mildly unpleasant (such as moderate drowsiness or dry mouth), these side effects can also be painful (such as acute dystonias), disfiguring (such as weight gain or tardive dyskinesia), and even life-threatening (such as myocarditis or agranulocytosis). It's significant to note that the adverse effect profiles of each antipsychotic drug vary and do not neatly fit into the first- or second-generation groups. Pharmacological side effects constrain the market for antipsychotic medications.

Antipsychotic Drugs Market Segmentation:

By Drug Type

First-generation Drugs (Standard / Typical Antipsychotic Agents)
- Thorazine (Chlorpromazine HCl)
- Serentil (Mesoridazine Besylate)
- Mellaril (Thioridazine HCl)
- Haldol (Haloperidol)
- Loxitane (Loxapine Succinate)
- Trilafon (Perphenazine)
- Navane (Thiothixene)
- Sordinol (Clopenthixol)
- Others
Second-generation Drugs (Atypical Antipsychotic Agents)
- Zyprexa (Olanzapine)
- Geodon (Ziprasidone)
- Seroquel (Quetiapine)
- Risperdal (Risperidone)
- Clozaril (Clozapine)
- Invega (Paliperidone)
- Asendin (Amoxapine)
- Latuda (Lurasidone)
- Others
Third-generation Drugs
- Abilify (Aripiprazole)
- Others

By Application

Schizophrenia
Bipolar Disorder
Dementia
Unipolar Depression
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. Strong psychiatric ailment prevalence in the area and the market presence of well-known biopharmaceutical businesses are two important variables contributing to the region's market supremacy. Bipolar disorder affects 2.8% of Americans annually, according to a report from the National Alliance on Mental Illness published in 2022. Also, bipolar disorder affects 7 million people, according to estimates. The region's significant antipsychotic adoption and technological prowess are further contributing reasons. Moreover, the region's great awareness of the seriousness of mental diseases is anticipated to fuel market expansion. Additionally, based on application; schizophrenia dominated the market in 2022.

Competitive Landscape:

Tier 1 players- established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Antipsychotic Drugs Market By Drug Type, By Application, By Distribution Channel and By Region.
To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1 . Years Considered for the Study
  3.2 . Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1 . Secondary Data
  1.1.1 . Key Data from Secondary Sources
  1.2 . Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Global Antipsychotic Drugs Market Variables, Trends and Scope
- 1. Market LineProducts Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Antipsychotic Drugs Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Antipsychotic Drugs Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Technology Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Technology Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Global Antipsychotic Drugs Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. First-generation Drugs (Standard / Typical Antipsychotic Agents)
  1.1. Thorazine (Chlorpromazine HCl)
  1.2. Serentil (Mesoridazine Besylate)
  1.3. Mellaril (Thioridazine HCl)
  1.4. Haldol (Haloperidol)
  1.5. Loxitane (Loxapine Succinate)
  1.6. Trilafon (Perphenazine)
  1.7. Navane (Thiothixene)
  1.8. Sordinol (Clopenthixol)
  1.9. Others
  2. Second-generation Drugs (Atypical Antipsychotic Agents)
  2.1. Zyprexa (Olanzapine)
  2.2. Geodon (Ziprasidone)
  2.3. Seroquel (Quetiapine)
  2.4. Risperdal (Risperidone)
  2.5. Clozaril (Clozapine)
  2.6. Invega (Paliperidone)
  2.7. Asendin (Amoxapine)
  2.8. Latuda (Lurasidone)
  2.9. Others
  3. Third-generation Drugs
  3.1. Abilify (Aripiprazole)
  3.2. Others
8. Global Antipsychotic Drugs Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Schizophrenia
  2. Bipolar Disorder
  3. Dementia
  4. Unipolar Depression
  5. Others
9. Global Antipsychotic Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
10. North America Antipsychotic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
11. Latin America Antipsychotic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
12. Europe Antipsychotic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
13. Asia Pacific Antipsychotic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
14. Middle East and Africa Antipsychotic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. GCC
  2.2. Israel
  2.3. South Africa
  2.4. Rest of MEA
  3. Market Size (USD Million) Forecast for MEA 2023-2031
15. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
- 1. AstraZeneca
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Pfizer, Inc.
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. Eli Lily and Co.
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Bristol- Myers Squibb
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. Johnson and Johnson
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. Allergen
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. GlaxoSmithKline plc
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Otsuka Pharmaceutical Co, Ltd.
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. AbbVie Inc.
  9.1. Company Overview
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
17. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by administrations
  5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients